PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study
Purpose: Metaplastic carcinoma of the breast (MCB) is a rare cancer characterized by the histologic presence of two or more histological cell types originating from epithelial and mesenchymal stem cells. Patients with metastatic MCB have a low response rate to conventional chemotherapy and poor surv...
Main Authors: | Ming-Han Yang, I-Chun Chen, Yen-Shen Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Journal of the Formosan Medical Association |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0929664618307034 |
Similar Items
-
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
by: Elan Gorshein, et al.
Published: (2021-06-01) -
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
by: F. Coussy, et al.
Published: (2020-02-01) -
Metaplastic carcinoma of breast
by: N Dewasi, et al.
Published: (2014-04-01) -
Metaplastic breast carcinoma with osteogenic component
by: Maha SA Abdel Hadi, et al.
Published: (2014-01-01) -
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
by: Isaac Kim, et al.
Published: (2021-06-01)